Sex differences in acute delta-9-tetrahydrocannabinol (Δ9-THC) response and tolerance as a function of mouse strain

[1]  S. Mitra,et al.  Mechanisms of cannabinoid tolerance. , 2023, Biochemical pharmacology.

[2]  Malabika Maulik,et al.  Cannabinoid Tolerance in S426A/S430A x β-Arrestin 2 Knockout Double-Mutant Mice , 2023, The Journal of Pharmacology and Experimental Therapeutics.

[3]  W. J. Lynch,et al.  Sex/Gender Differences in the Time-Course for the Development of Substance Use Disorder: A Focus on the Telescoping Effect , 2022, Pharmacological Reviews.

[4]  D. Morgan,et al.  Sex Differences in Tolerance to Delta-9-Tetrahydrocannabinol in Mice With Cisplatin-Evoked Chronic Neuropathic Pain , 2021, Frontiers in Molecular Biosciences.

[5]  Angela N Henderson-Redmond,et al.  Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (Δ9-THC) , 2021, Psychopharmacology.

[6]  E. Weerts,et al.  Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations , 2021, Psychopharmacology.

[7]  N. Bhattacharyya,et al.  Prevalence of chronic pain among adults in the United States. , 2021, Pain.

[8]  Megan K. Mulligan,et al.  Sex and Strain Variation in Initial Sensitivity and Rapid Tolerance to Δ9–Tetrahydrocannabinol , 2020, Cannabis and cannabinoid research.

[9]  J. Wiley,et al.  Sex, species and age: Effects of rodent demographics on the pharmacology of ∆9-tetrahydrocanabinol , 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  T. Kerr,et al.  Lasting effects of repeated ∆9‐tetrahydrocannabinol vapour inhalation during adolescence in male and female rats , 2019, British journal of pharmacology.

[11]  K. Mackie,et al.  c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner , 2019, Neuropharmacology.

[12]  C. Breivogel,et al.  Sex, THC, and hormones: Effects on density and sensitivity of CB1 cannabinoid receptors in rats. , 2019, Drug and alcohol dependence.

[13]  James M. Dahlhamer,et al.  Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016 , 2018, MMWR. Morbidity and mortality weekly report.

[14]  M. Cole,et al.  Tolerance to hypothermic and antinoceptive effects of ∆9-tetrahydrocannabinol (THC) vapor inhalation in rats , 2018, Pharmacology Biochemistry and Behavior.

[15]  D. Morgan,et al.  Sex differences in antinociceptive response to &Dgr;-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test , 2018, Neuroreport.

[16]  L. Radbruch,et al.  Cannabis-based medicines for chronic neuropathic pain in adults. , 2018, The Cochrane database of systematic reviews.

[17]  J. Wiley,et al.  Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats. , 2017, Drug and alcohol dependence.

[18]  M. Haney,et al.  Sex-dependent effects of cannabis-induced analgesia. , 2016, Drug and alcohol dependence.

[19]  S. Klein,et al.  Sex differences in immune responses , 2016, Nature Reviews Immunology.

[20]  C. Cuttler,et al.  Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users , 2016, Cannabis and cannabinoid research.

[21]  H. de Wit,et al.  A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial , 2015, PloS one.

[22]  A. Childress,et al.  Sex differences in associations between cannabis craving and neural responses to cannabis cues: Implications for treatment. , 2015, Experimental and clinical psychopharmacology.

[23]  R. Nahin.  Estimates of pain prevalence and severity in adults: United States, 2012. , 2015, The journal of pain : official journal of the American Pain Society.

[24]  Peter Kreiner,et al.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. , 2015, Annual review of public health.

[25]  S. Nixon,et al.  Sex differences in drug use among polysubstance users. , 2014, Drug and alcohol dependence.

[26]  J. Wiley,et al.  Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat. , 2014, Drug and alcohol dependence.

[27]  C. Pike,et al.  Diet-induced obesity and low testosterone increase neuroinflammation and impair neural function , 2014, Journal of Neuroinflammation.

[28]  Alisha Mcbride,et al.  Cyclic ovarian hormone modulation of supraspinal Δ9-tetrahydrocannabinol-induced antinociception and cannabinoid receptor binding in the female rat , 2014, Pharmacology Biochemistry and Behavior.

[29]  D. N. Klein,et al.  Natural course of cannabis use disorders , 2014, Psychological Medicine.

[30]  K. Mackie,et al.  Mutation of Putative GRK Phosphorylation Sites in the Cannabinoid Receptor 1 (CB1R) Confers Resistance to Cannabinoid Tolerance and Hypersensitivity to Cannabinoids in Mice , 2014, The Journal of Neuroscience.

[31]  W. Fratta,et al.  Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: effect of ovarian hormones. , 2014, Current pharmaceutical design.

[32]  M. Haney,et al.  Investigation of sex-dependent effects of cannabis in daily cannabis smokers. , 2014, Drug and alcohol dependence.

[33]  C. Blanco,et al.  Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. , 2013, Drug and alcohol dependence.

[34]  Peter T. Nguyen,et al.  β-Arrestin2 Regulates Cannabinoid CB1 Receptor Signaling and Adaptation in a Central Nervous System Region–Dependent Manner , 2012, Biological Psychiatry.

[35]  R. Craft,et al.  Sex Differences in Cannabinoid 1 vs. Cannabinoid 2 Receptor-Selective Antagonism of Antinociception Produced by Δ9-Tetrahydrocannabinol and CP55,940 in the Rat , 2012, Journal of Pharmacology and Experimental Therapeutics.

[36]  R. Craft,et al.  Antinociception and sedation following intracerebroventricular administration of Δ9-tetrahydrocannabinol in female vs. male rats , 2011, Behavioural Brain Research.

[37]  L. Leresche,et al.  Age and gender trends in long-term opioid analgesic use for noncancer pain. , 2010, American journal of public health.

[38]  B. Gorzalka,et al.  Estrogenic regulation of limbic cannabinoid receptor binding , 2010, Psychoneuroendocrinology.

[39]  Beth M. Anderson,et al.  Sex Differences in the Effects of Marijuana on Simulated Driving Performance , 2010, Journal of psychoactive drugs.

[40]  C. Ehlers,et al.  Cannabis dependence in the San Francisco Family Study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability. , 2010, Addictive behaviors.

[41]  C. Rutter,et al.  Trends in long‐term opioid therapy for chronic non‐cancer pain , 2009, Pharmacoepidemiology and drug safety.

[42]  G. Juckel,et al.  Psychomotor performance in relation to acute oral administration of Δ9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[43]  M. Haney.  Opioid Antagonism of Cannabinoid Effects: Differences between Marijuana Smokers and Nonmarijuana Smokers , 2007, Neuropsychopharmacology.

[44]  G. Cavaletti,et al.  Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy , 2007, Cellular and Molecular Life Sciences.

[45]  H. Bradshaw,et al.  Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[46]  S. Heishman,et al.  Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. , 2006, The American journal on addictions.

[47]  D. Penetar,et al.  Transdermal nicotine alters some of marihuana's effects in male and female volunteers. , 2005, Drug and alcohol dependence.

[48]  M. Cebeira,et al.  Cannabinoid tolerance and dependence: A review of studies in laboratory animals , 2005, Pharmacology Biochemistry and Behavior.

[49]  H. Kranzler,et al.  Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. , 2004, Drug and alcohol dependence.

[50]  C. Guaza,et al.  Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. , 2002, Brain research. Developmental brain research.

[51]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[52]  R. Craft,et al.  Sex differences in antinociceptive and motoric effects of cannabinoids. , 2001, European journal of pharmacology.

[53]  J. Manzanares,et al.  Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. , 2000, Biochemical and biophysical research communications.

[54]  J. Mogil,et al.  Sex differences in supraspinal morphine analgesia are dependent on genotype. , 1999, The Journal of pharmacology and experimental therapeutics.

[55]  R. Hampson,et al.  Effects of Chronic Treatment with Δ9-Tetrahydrocannabinol on Cannabinoid-Stimulated [35S]GTPγS Autoradiography in Rat Brain , 1996, The Journal of Neuroscience.

[56]  K. Mackie,et al.  Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[57]  P. Casellas,et al.  Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells (*) , 1995, The Journal of Biological Chemistry.

[58]  T. Palomo,et al.  Downregulation of rat brain cannabinoid binding sites after chronic Δ 9-tetrahydrocannabinol treatment , 1994, Pharmacology Biochemistry and Behavior.

[59]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[60]  K. Mackie,et al.  Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. , 1993, Molecular pharmacology.

[61]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[62]  A. Howlett.  Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. , 1985, Molecular pharmacology.

[63]  R. Pickering,et al.  DSM-5 cannabis use disorder in the National Epidemiologic Survey on Alcohol and Related Conditions-III: Gender-specific profiles. , 2018, Addictive behaviors.

[64]  Self-Concept Variables.  Sex Differences in , 2016 .

[65]  K. Vowles,et al.  Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis , 2019 .

[66]  D. Cocchetto,et al.  Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man , 2004, Psychopharmacology.

[67]  Willem Jan van der Veen,et al.  Age and gender , 2004 .

[68]  H. Loh,et al.  Molecular mechanisms and regulation of opioid receptor signaling. , 2000, Annual review of pharmacology and toxicology.

[69]  Ying-Xian Pan,et al.  Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. , 1994, Life sciences.

[70]  F. Rodríguez de Fonseca,et al.  Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. , 1994, Life sciences.

[71]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .